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T regulatory (Treg) cells are one of the key players in the immune tolerance network, and 
a plethora of manuscripts have described their development and function in the course 
of the last two decades. Nevertheless, it is still a matter of debate as to which mecha-
nisms and agents are employed by Treg cells, providing the basis of their suppressive 
potency. One of the important candidates is cyclic AMP (cAMP), which is long known 
as a potent suppressor at least of T cell activation and function. While this suppressive 
function by itself is widely accepted, the source and the mechanism of action of cAMP 
are less clear, and a multitude of seemingly contradictory data allow for, in principle, two 
different scenarios of cAMP-mediated suppression. In one scenario, Treg cells contain 
high amounts of cAMP and convey this small molecule via gap junction intercellular com-
munication directly to the effector T cells (Teff) leading to their suppression. Alternatively, 
it was shown that Treg cells represent the origin of considerable amounts of adenosine, 
which trigger the adenylate cyclases in Teff cells via A2A and A2B receptors, thus strongly 
increasing intracellular cAMP. This review will present and discuss initial findings and 
recent developments concerning the function of cAMP for Treg cells and its impact on 
immune regulation.
Keywords: cyclic AMP, regulatory T cells, FOXP3, adenosine, immune regulation, immune tolerance network, 
suppression
inTRODUCTiOn
The immune system commands an impressive armament to repel invading microorganisms. The 
overwhelming part of such an antimicrobial immune response is coordinated and initiated by CD4+ 
T helper (Th) cells, which recognize foreign antigens through their T cell receptor after presentation 
by antigen-presenting cells. A huge Th cell receptor repertoire ensures that almost all pathogens can 
be recognized and subsequently be eliminated. However, this virtually exhaustless T cell receptor 
repertoire obviously bears the risk of containing autoaggressive T cells (1). This was demonstrated 
by the transfer of naive Th cells, which represent approximately 90% of all peripheral CD4+ Th cells 
into T cell-deficient mice that led to a multitude of autoimmune diseases indicating that a consider-
able part of this Th cell population is potentially autoreactive (2–4). These potentially autoreactive 
naive Th cells are usually kept in check when CD25+ peripheral Th cells are cotransferred together 
with CD25− T cells, thus indicating that this residual T cell compartment that was separated from 
naive T cells before transfer is capable to prevent autoimmune symptoms (5, 6). Today, we know 
that this suppressive Th cell population mainly consists of T regulatory (Treg) cells which were 
found to control T effector (Teff) cells in vitro in a contact-dependent manner. The Treg/Teff cell 
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interaction was shown to suppress preferentially IL-2 production 
and proliferation of the Teff cells – a hallmark of clonal T cell 
expansion (7). Concerning the suppressive mechanism(s), the 
usage of cytokine-deficient and cytokine receptor-deficient mice 
could exclude that IL-10 and TGF-β – at least in vitro – mediated 
the suppressive properties of Treg cells (7, 8). Subsequently, the 
characterization of the transcription factor forkhead box protein 
3 (FOXP3), as a lineage-specific marker for Treg cells, and the 
generation of FOXP3 reporter mice strongly boosted Treg cell 
research. Continuative analyses revealed that FOXP3 is crucial 
for Treg cell development and function (9–11). These findings 
provided the opportunity to screen the FOXP3-regulated Treg 
cell transcriptome which revealed that the expression of a cyclic 
AMP (cAMP)-degrading phosphodiesterase (PDE3b) is strongly 
repressed in Treg cells, whereas the expression of ectonucleoti-
dases (CD39 and CD73) as well as expression of adenylyl cyclase 
9 (AC9), an enzyme promoting de novo generation of intracellular 
cAMP, was upregulated (12, 13). Therefore, reduced expression 
of phosphodiesterase (PDE3b) implied a decreased degradation 
of intracellular cAMP accompanied by a strong production of 
cAMP due to strong expression of AC9, while elevated expres-
sion of CD39/CD73 should lead to an increased generation of 
extracellular adenosine in the proximity of Treg cells. Hence, 
FOXP3-dependent transcriptional profiling suggested that the 
suppressive properties of Treg cells is based at least partially on 
comparatively high amounts of intracellular cAMP concomitantly 
with an enhanced ability to generate extracellular adenosine from 
adenosine triphosphate (ATP) [reviewed in Ref. (14, 15)].
inTRACeLLULAR cAMP enABLeS Treg 
CeLLS TO MAinTAin THe BALAnCe OF 
THe iMMUne TOLeRAnCe neTwORK 
DURinG iMMUne HOMeOSTASiS
Intracellular cAMP has long been recognized as a potent inhibi-
tor of T cell activation. Especially, agents that elevated cAMP in 
T cells like cholera toxin, prostaglandin E2, and forskolin were 
found to strongly impair IL-2 production and T cell proliferation 
(16–19). Comparative analyses of intracellular cAMP revealed 
that Treg cells contained high intracellular amounts of cAMP, 
while it was hardly detectable in Teff cells (20). In addition, 
co-activation of cocultured Treg and Teff cells resulted in a con-
siderable intracellular increase of cAMP in Teff cells, suggesting 
a cell contact-dependent transfer of cAMP. One possibility for 
cell contact-dependent transfer was gap junction intercellular 
communication (GJIC). GJIC was demonstrated by employing 
the fluorescent dye calcein which can only be transferred between 
T cells by gap junctions (21, 22). The functional consequence of 
such a GJIC-mediated transfer of cAMP between Treg and Teff 
cells was a strong reduction of IL-2 expression, and as a conse-
quence, inhibition of proliferation, which was both reversed in 
the presence of the GJIC inhibitor GAP27. In addition, it was 
shown that the coculture of murine Treg cells and dendritic cells 
(DC) led to a strong elevation of cAMP in DC concomitantly 
with an immediate downregulation of CD80/CD86 costimula-
tors (23). This Treg cell-mediated suppression of DC activation 
via transfer of cAMP was suggested to be decisively involved in 
the control of a Graft-versus-host disease (GvHD) by Treg cells. 
Accordingly, the potency of Treg cells to ameliorate a GvHD was 
found to be strongly increased in the presence of PDE-inhibitors 
like rolipram (24). In agreement with these findings, it was 
shown that neonatal human Treg cells suppress DC activation by 
CTLA-4 and cAMP (25).
The importance of GJIC for Treg-mediated suppression was 
recently emphasized by the finding that diabetic NOD mice 
showed an impaired expression of connexin 43 (Cx43), an 
important component of gap junctions, leading in consequence 
to a strongly reduced suppressive potency of their Treg cells (26). 
Overexpression of Cx43 in such Treg cells increased their suppres-
sive properties roughly to the level of non-diabetic young NOD 
mice. The same outcome could be observed when Cx43-mediated 
GJIC was strengthened via the treatment with alpha-connexin 
carboxyl-terminal peptide 1 (αCT-1). αCT-1 is a unique synthetic 
peptide that mimics a cytoplasmic regulatory domain of Cx43 
and that specifically disrupts the interaction between Cx43 und 
its binding partner zonula occludens (ZO)-1, ultimately leading 
to an enhanced gap junction aggregation (27, 28). However, 
treatment with αCT-1 failed when Cx43-deficient Treg cells were 
used, indicating the specificity of action of this agent (26).
The comparatively high content of cAMP in Treg cells was 
described to result from a strong FOXP3-mediated reduction of 
PDE3b expression concomitantly with a considerable suppressive 
activity of this T cell type (29). Further analyses of the underlying 
molecular mechanisms revealed that FOXP3 not only binds and 
regulates the Pde3b locus but also additionally downregulates 
expression of the miRNA miR-142-3p, a potent inhibitor of 
AC9, which catalyzes the conversion of ATP to 3′,5′-cAMP. As 
a consequence of the impaired targeting of AC9 mRNA due to 
reduced miR-142-3p expression in Treg cells, these cells contain 
high levels of AC9, driving elevated intracellular cAMP level. 
Accordingly, transfection of Treg cells with miR-142-3p not only 
reduced AC9 expression and intracellular cAMP levels but also 
considerably impaired the suppressive properties of these Treg 
cells. The same effect was observed when Treg cells were trans-
fected with AC9 siRNA, again preventing de novo generation of 
intracellular cAMP by AC9. Thus, FOXP3 strongly promotes 
AC9-dependent intracellular cAMP production by suppress-
ing expression of miR-142-3p and PDE3b as well. Concerning 
human Treg cells, it was shown that polyclonal activation as 
well as activation via CD4, known to induce tolerance, strongly 
increased the concentration of intracellular cAMP. The irrevers-
ible blockade of adenylate cyclases (AC) by MDL12 inhibited this 
upregulation of cAMP concomitantly with a strong impairment 
of their suppressive potency – in vitro as well as in vivo – and led 
to an increased proliferation of these AC-blocked Treg cells (30). 
Nevertheless, such Treg cells regained their suppressive proper-
ties after several days of expansion probably as a consequence 
of the dilution of the AC inhibitor MDL12. Similar to MDL12, 
the ectopic expression of cAMP-degrading phosphodiesterase, 
PDE4c, also prevented the increase of intracellular cAMP in 
human Treg cells and strongly impaired their suppressive capac-
ity. By contrast, it could be shown that the inhibition of PDE4 
by rolipram strongly enhanced the suppressive potency of Treg 
FiGURe 1 | Adenosine strongly improves the suppressive influence of 
Treg cell-derived cAMP in the course of inflammation. During immune 
homeostasis, Treg cells stabilize the ITN with the aid of endogenous cAMP 
that is driven by FOXP3, which indirectly upregulates adenylate cylase 9 
(AC9) through the inhibition of miR142-3p and which concomitantly 
downregulates cAMP-degrading phosphodiesterase 3b (PDE3b). As a result, 
Treg cells contain comparatively high amounts of cAMP leading to the 
suppression of Teff cells and DC via gap junctional intercellular 
communication (GJIC). Inflammation in combination with metabolic stress 
and tissue injury results in a massive release of ATP, which represents a 
powerful danger signal that serves as an additional local inflammatory 
booster that bears the risk of collateral damage by uncontrollable immune 
reactions. Therefore, metabolization of ATP by ectonucleotidases CD39 and 
CD73 that leads to increased local amounts of adenosine prevents such a 
fatal development especially through triggering the adenosine receptor A2A 
(A2AR) on Treg and Teff cells and DC as well. The A2AR-mediated elevation of 
intracellular cAMP inhibits the activation of Teff cells and impairs the 
accessory function of DC and simultaneously strongly improves the 
suppressive activity of Treg cells.
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cells in vitro and in vivo. Transfer of rolipram-treated Treg cells 
strongly inhibited asthma symptoms in a prophylactic as well as 
a therapeutic preclinical animal model of experimental asthma 
(31). As a consequence of Treg–Th2 interaction in vivo, a strong 
increase of intracellular cAMP could be observed in lung-resident 
Th2 cells. Additional studies revealed that asthma-promoting Th1 
and Th2 cells exhibited a similar increase of intracellular cAMP 
after contact with Treg cells in vitro and in vivo, but that Th1 cells 
were far more sensitive to Treg-mediated suppression (32). This 
was in agreement with the finding that comparatively high cAMP 
contents are needed to strongly inhibit Th2-derived IL-4 produc-
tion, while comparatively low cAMP concentrations are sufficient 
in suppressing IL-2 production and subsequent proliferation of 
Th1 cells (18).
eXTRACeLLULAR ADenOSine iS 
ReQUiReD TO LiMiT A POTenTiALLY 
SeLF-DeSTRUCTive inFLAMMATORY 
iMMUne ReSPOnSe
Inflammatory immune reactions are accompanied by the release 
of high amounts of ATP in the extracellular space where it is con-
verted into AMP by CD39 and dephosphorylated to adenosine by 
CD73 (33). Adenosine has strong anti-inflammatory influence on 
immune cells preferentially by triggering A2A and A2B receptors 
leading to the generation of intracellular cAMP. Interestingly, the 
anti-inflammatory action of adenosine is exploited by tumors 
where adenosine was shown to accumulate, thereby preventing 
immunological tumor regression (34, 35). The tumor-protective 
role of adenosine was underlined using mice deficient for the 
genes Adora2a, encoding for A2A or Adora2b, encoding for A2B 
receptors which show enhanced elimination of tumors com-
pared to A2A and A2B receptor sufficient wild-type mice (35–37). 
Among mouse T cells, CD39 and CD73 were described to be 
preferentially co-expressed in Treg cells (38). This was in agree-
ment with the finding that the expression of Entpd1 (CD39) and 
Nt5e (CD73) was shown to be upregulated by FOXP3 (12). In line 
with this, inhibitors of CD39 and CD73 decreased the suppressive 
capacity of Tregs (39–41). Conclusively, Entpd1-deficient (CD39-
deficient) Treg cells exhibited impaired suppressive properties 
in vitro in a coculture assay as well as in vivo using an allogeneic 
skin graft model upon cotransfer of Treg/Teff cells indicating the 
importance of this ectonucleotidase for the suppressive function 
of Treg cells. Similarly, in a model of acute lung injury (ALI), 
adoptive transfer of Nt5e-deficient (CD73-deficient) Treg cells 
failed to resolve ALI adequately, whereas transfer of wild-type 
Treg cells led to normal resolution (42). Furthermore, it was 
shown in a model of acute kidney injury that DC treated with 
an A2A receptor agonist could protect the kidney by suppressing 
DC-dependent NKT cell activation, suggesting a strong immu-
nosuppressive influence of adenosine on the accessory functions 
of such DC (43).
Interestingly, Teff cells that represent a major target of 
Treg cell suppressive activity were found to express the T cell-
typical adenosine receptor A2A not before day 4 after activa-
tion, thus excluding immediate early suppressive influence by 
this mechanism (38). Accordingly, the authors stated that the 
adenosine-driven suppression was most probably functional 
during the late phases of Teff cell activation. Nonetheless, the 
importance of A2A receptors on Teff cells for Treg cell-mediated 
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